



Supplemental Figure 3. Death-censored graft survival in the CTS cohort among (A) 412 pre-sensitized recipients (panel reactivity > 0%), (B) 680 recipients with 4–6 HLA-A+B+DR mismatches, and (C) 227 recipients with treated rejection during the first-post-transplant year, in relation to *KLRC2* genotype.